Oleandrin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oleandrin
Accession Number
DB12843
Type
Small Molecule
Groups
Experimental, Investigational
Description

Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.

Structure
Thumb
3D
Similar Structures
Synonyms
  • Anvirzel
  • Oleandrina
External IDs
NSC-692219
Categories
UNII
II95UDU7I4
CAS number
465-16-7
Weight
Average: 576.727
Monoisotopic: 576.329833126
Chemical Formula
C32H48O9
InChI Key
JLPDBLFIVFSOCC-XYXFTTADSA-N
InChI
InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
IUPAC Name
(1S,2S,5S,7R,10R,11S,13S,14R,15R)-11-hydroxy-5-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate
SMILES
CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Oleandrin.
3,5-diiodothyropropionic acidThe serum concentration of Oleandrin can be increased when it is combined with 3,5-diiodothyropropionic acid.
6-Deoxyerythronolide BThe serum concentration of Oleandrin can be increased when it is combined with 6-Deoxyerythronolide B.
AbaloparatideThe serum concentration of Oleandrin can be increased when it is combined with Abaloparatide.
AcebutololAcebutolol may increase the bradycardic activities of Oleandrin.
Acetylsalicylic acidThe serum concentration of Oleandrin can be decreased when it is combined with Acetylsalicylic acid.
AgmatineThe serum concentration of Oleandrin can be increased when it is combined with Agmatine.
AlcuroniumThe risk or severity of Cardiac Arrhythmia can be increased when Alcuronium is combined with Oleandrin.
AldoxorubicinOleandrin may decrease the cardiotoxic activities of Aldoxorubicin.
AlfacalcidolThe risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Alfacalcidol is combined with Oleandrin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11541511
PubChem Substance
347829006
ChemSpider
9716290
ChEBI
59030
ChEMBL
CHEMBL1075789
Wikipedia
Oleandrin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentChemotherapeutic Agent Toxicity / Lung Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00299 mg/mLALOGPS
logP2.1ALOGPS
logP2.95ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)6.82ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.75 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity148.45 m3·mol-1ChemAxon
Polarizability63.2 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Cardenolide glycosides and derivatives
Alternative Parents
Steroidal glycosides / Steroid esters / 14-hydroxysteroids / Hexoses / O-glycosyl compounds / Oxanes / Butenolides / Dicarboxylic acids and derivatives / Tertiary alcohols / Enoate esters
show 9 more
Substituents
Cardanolide-glycoside / Steroidal glycoside / Steroid ester / 14-hydroxysteroid / Hydroxysteroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / 2-furanone / Dicarboxylic acid or derivatives
show 23 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
steroid ester, steroid saponin, 14beta-hydroxy steroid, cardenolide glycoside (CHEBI:59030)

Drug created on October 20, 2016 18:39 / Updated on November 02, 2018 07:30